Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a study in Frontiers of Medicine has identified a pivotal role for CD39 ...

A new immune structure found in liver tumors could improve treatment for liver cancer patients. These structures are linked ...

Know what Hepatocellular Carcinoma is and why is this most common liver cancer among adults is on the rise? Read on.

Hepatocellular carcinoma (HCC) is one of the most fatal malignancies. Epigenetic mechanisms have revealed that noncoding RNAs ...

A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to ...

Transarterial chemoembolization (TACE) is currently the most common approach for the management of hepatocellular carcinoma (HCC) without curative options. TACE consists of the injection of ...

A new immune cell biomarker has been discovered that can predict the effectiveness of immune anticancer treatment in patients ...

The following is a summary of the study "Clinical study on conversion therapy of hepatocellular carcinoma - summary and ...

International perspectives on when to utilize transarterial radioembolization to increase the likelihood of curative outcomes ...